Kathy Oubre, MS, comments on the recent criticism regarding the use of biosimilars
1:22
Kathy Oubre, MS, comments on the recent criticism regarding the use of biosimilars
Kathy Oubre, MS, offers opinion on whether biosimilars are living up to their estimated cost savings
2:35
Kathy Oubre, MS, offers opinion on whether biosimilars are living up to their estimated cost savings
Kathy Oubre, MS, speculates on the future of biosimilars
2:36
Kathy Oubre, MS, speculates on the future of biosimilars
Kathy Oubre, MS, considers how comfortable physicians and payers are with biosimilars
2:00
Kathy Oubre, MS, considers how comfortable physicians and payers are with biosimilars
Bo Gamble, on the most important critical success factors when adopting a new payment model
3:16
Bo Gamble, on the most important critical success factors when adopting a new payment model
Alti Rahman, MHA\MBA, CSSBB, reflects on social determinants of health in cancer care
3:07
Alti Rahman, MHA\MBA, CSSBB, reflects on social determinants of health in cancer care
Bo Gamble, discusses the impact of consolidation on the delivery of cancer care
3:52
Bo Gamble, discusses the impact of consolidation on the delivery of cancer care
Bo Gamble, speculates on the future of alternative payment models (APMs)
3:05
Bo Gamble, speculates on the future of alternative payment models (APMs)
Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape
3:02
Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape
Alti Rahman, MHA\MBA, CSSBB, regarding the impact of consolidation on the delivery of cancer care
2:39
Alti Rahman, MHA\MBA, CSSBB, regarding the impact of consolidation on the delivery of cancer care
Bo Gamble, considers how value & quality may vary across community oncology practices
3:17
Bo Gamble, considers how value & quality may vary across community oncology practices
Bo Gamble, compares and contrasts the definition of value and quality as it relates to cancer care
1:59
Bo Gamble, compares and contrasts the definition of value and quality as it relates to cancer care
Alti Rahman, MHA\MBA, CSSBB, considers how oncology practices can reduce costs & maximize savings
2:13
Alti Rahman, MHA\MBA, CSSBB, considers how oncology practices can reduce costs & maximize savings
Alti Rahman, MHA\MBA, CSSBB, provides perspective on the challenges facing oncology practices
2:36
Alti Rahman, MHA\MBA, CSSBB, provides perspective on the challenges facing oncology practices
Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists
2:19
Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists
Johnetta Blakely, MD, offers an example of how HEOR has impacted cancer care at Tennessee Oncology
3:04
Johnetta Blakely, MD, offers an example of how HEOR has impacted cancer care at Tennessee Oncology
Johnetta Blakely, MD, elaborates on how HEOR may be used in conjunction with real-world evidence
1:47
Johnetta Blakely, MD, elaborates on how HEOR may be used in conjunction with real-world evidence
Johnetta Blakely, MD, considers how HEOR data influences payer decisions
1:32
Johnetta Blakely, MD, considers how HEOR data influences payer decisions
Johnetta Blakely, MD, explains the role of HEOR as it contributes to value-based care
2:13
Johnetta Blakely, MD, explains the role of HEOR as it contributes to value-based care
Jonathan E. Levitt, Esq., on the experience of hem/onc groups unable to enter into a PBM network
1:08
Jonathan E. Levitt, Esq., on the experience of hem/onc groups unable to enter into a PBM network
Jonathan E. Levitt, Esq., explains how copay aggregators differ across PBMs
3:31
Jonathan E. Levitt, Esq., explains how copay aggregators differ across PBMs
Jonathan E. Levitt, Esq., offers opinion on PBM consolidation & the changing dynamics of cancer care
3:44
Jonathan E. Levitt, Esq., offers opinion on PBM consolidation & the changing dynamics of cancer care
Jonathan E. Levitt, Esq., considers how PBM behaviors are changing as a result of the pandemic
1:47
Jonathan E. Levitt, Esq., considers how PBM behaviors are changing as a result of the pandemic
Jonathan E. Levitt, Esq., explains how DIR fees impact practice costs and efficiencies
2:42
Jonathan E. Levitt, Esq., explains how DIR fees impact practice costs and efficiencies
Jonathan E. Levitt, Esq., discusses the state of payer mandates for white / brown bagging
3:31
Jonathan E. Levitt, Esq., discusses the state of payer mandates for white / brown bagging
Sara Riordan, MS, CGC, on the role of genetic counselors as part of a multidisciplinary cancer team
1:57
Sara Riordan, MS, CGC, on the role of genetic counselors as part of a multidisciplinary cancer team
Sara Riordan, MS, CGC, regarding the significance of biomarker testing in early-stage cancer
1:52
Sara Riordan, MS, CGC, regarding the significance of biomarker testing in early-stage cancer
Sara Riordan, MS, CGC, on how genetic signature & biomarker tests are used in cancer management
2:36
Sara Riordan, MS, CGC, on how genetic signature & biomarker tests are used in cancer management
Sara Riordan, MS, CGC, elaborates on the unmet needs in biomarker testing
2:02
Sara Riordan, MS, CGC, elaborates on the unmet needs in biomarker testing
Lalan S. Wilfong, MD, discusses key takeaways from the 2021 Virtual Community Oncology Conference
1:03
Lalan S. Wilfong, MD, discusses key takeaways from the 2021 Virtual Community Oncology Conference